▎When the editor of WuXi AppTec's content team talks about immunity to the new coronavirus, the first thing people think of may be the neutralizing effect of neutralizing antibodies.
[First issue] Heqirui Medicine, dedicated to source innovation, successfully completed US$56 million in Series B financing to accelerate the creation of a global innovative R&D platform
Time of Update: 2021-05-22
The Heqirui team led by Professor Xiao Ruiping has an international vision and experience, and is committed to the research and development of first-in-class innovative drugs based on an in-depth understanding of translational medicine.
Cell Highlights | XIST-mediated X chromosome inactivation participates in the regulation of immune differences between the sexes
Time of Update: 2021-05-10
XIST binding protein TRIM28, it was found that TRIM28 can inhibit the expression of part of the X chromosome gene by regulating the retention of Pol II in the promoter. By analyzing the single-cell transcriptomes
Recombinant new coronavirus vaccine (CHO cells) is approved for emergency use | Transformation Highlights
Time of Update: 2021-05-09
On March 10, 2021, the recombinant novel coronavirus vaccine (CHO cell) jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongkoma Biopharmaceutical Co.
Trends in Immunology Editor's Choice: 17 Best Reviews in 2020
Time of Update: 2021-05-09
Looking back at 2021, Trends in Immunology is pleased to launch this collection of papers, introducing the best review articles we have published in the past year to everyone.
Seroconversion rate of influenza patients is related to severity of infection | Cell Press Express
Time of Update: 2021-05-09
Medicine On April 20th, the research team of St.
PLoS Pathogens: Discover new clues for mother-to-child transmission of HIV
Time of Update: 2021-05-08
The results of the study indicate that the circulating mother virus is resistant to bnAb- mediated neutralization, but not resistant to autologous plasma neutralization, which indicates an increased risk of mother-to-child transmission.
Hengrui Medicine's SHR-A1904 for injection was approved for clinical use in the treatment of advanced solid tumors
Time of Update: 2021-05-08
has recently received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" on SHR-A1904 for injection, which will be used in the near future.
Nat Neurosci.: A new direction in the treatment of multiple sclerosis: microglia can remove toxic lipids in multiple sclerosis
Time of Update: 2021-05-08
Dong and colleagues studied the mechanisms that mediate neurodegeneration in multiple sclerosis and determined the direct role of oxidized phosphatidylcholines (OxPCs) in driving the death of central nerve cells.
China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials
Time of Update: 2021-05-02
China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.
FDA revokes emergency use authorization for Eli Lilly's new crown antibody drug
Time of Update: 2021-05-02
>
Editor: Wu Bin
>
As the new crown virus continues to mutate, the US pharmaceutical giant accidentally "lay the gun". On Friday, the US Food
BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use
Time of Update: 2021-05-02
On April 9, 2021, the CDE official website showed that BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use, and the indication is advanced solid tumors.
Biotay Adalimumab adds "children's plaque psoriasis" indication
Time of Update: 2021-04-29
As of the announcement date, the approved indications for Glorious® are ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, uveitis and plaque psoriasis in children.
